JPH11304804A - Peroxide active material deteting composition - Google Patents
Peroxide active material deteting compositionInfo
- Publication number
- JPH11304804A JPH11304804A JP14203198A JP14203198A JPH11304804A JP H11304804 A JPH11304804 A JP H11304804A JP 14203198 A JP14203198 A JP 14203198A JP 14203198 A JP14203198 A JP 14203198A JP H11304804 A JPH11304804 A JP H11304804A
- Authority
- JP
- Japan
- Prior art keywords
- iron
- iii
- complex
- ascorbic acid
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims description 10
- 150000002978 peroxides Chemical class 0.000 title claims description 7
- 239000011149 active material Substances 0.000 title 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000002432 hydroperoxides Chemical class 0.000 claims abstract description 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 6
- 125000000732 arylene group Chemical group 0.000 claims description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 50
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 25
- 239000011668 ascorbic acid Substances 0.000 abstract description 25
- 229960005070 ascorbic acid Drugs 0.000 abstract description 24
- TZUOAFAFVLCVOL-UHFFFAOYSA-H iron(3+);phthalate Chemical group [Fe+3].[Fe+3].[O-]C(=O)C1=CC=CC=C1C([O-])=O.[O-]C(=O)C1=CC=CC=C1C([O-])=O.[O-]C(=O)C1=CC=CC=C1C([O-])=O TZUOAFAFVLCVOL-UHFFFAOYSA-H 0.000 abstract description 9
- 210000002700 urine Anatomy 0.000 abstract description 9
- 238000005259 measurement Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract description 2
- 230000002829 reductive effect Effects 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- ZJBMGHSHQUAKKI-UHFFFAOYSA-L iron(2+);phthalate Chemical compound [Fe+2].[O-]C(=O)C1=CC=CC=C1C([O-])=O ZJBMGHSHQUAKKI-UHFFFAOYSA-L 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- -1 iron (III) ions Chemical class 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- HQWKKEIVHQXCPI-UHFFFAOYSA-L disodium;phthalate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C([O-])=O HQWKKEIVHQXCPI-UHFFFAOYSA-L 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 1
- HFDLDPJYCIEXJP-UHFFFAOYSA-N 6-methoxyquinoline Chemical compound N1=CC=CC2=CC(OC)=CC=C21 HFDLDPJYCIEXJP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000004700 cobalt complex Chemical class 0.000 description 1
- JAWGVVJVYSANRY-UHFFFAOYSA-N cobalt(3+) Chemical compound [Co+3] JAWGVVJVYSANRY-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 description 1
- 239000011615 dehydroascorbic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、液体試料中のアス
コルビン酸などの還元性物質による影響を排除できる過
酸化活性物質検出用組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition for detecting a peroxide active substance which can eliminate the influence of a reducing substance such as ascorbic acid in a liquid sample.
【０００２】[0002]
【従来の技術】液体試料中のヘモグロビンといった過酸
化活性を有する物質を検出または定量する場合、試料中
に存在するアスコルビン酸などは強還元剤として作用す
るので、過酸化活性物質の測定に種々の悪影響を与える
ことが知られている。このようなアスコルビン酸などの
還元性物質の影響を回避する為に、金属イオンを酸化剤
として用いる技術が開発されてきている。2. Description of the Related Art When detecting or quantifying a substance having a peroxidative activity such as hemoglobin in a liquid sample, ascorbic acid or the like present in the sample acts as a strong reducing agent. It is known to have a negative effect. In order to avoid the influence of such a reducing substance such as ascorbic acid, a technique using a metal ion as an oxidizing agent has been developed.
【０００３】まず、ザ・ジャーナル・オブ・ジ・アメ
リカン・ケミカル・ソサエティ（Ｊ．Ａｍ．Ｃｈｅｍ．
Ｓｏｃ），８９，４１７６（１９６７）と、同８９，７
１０４（１９６７）；９０，３３８６（１９６８）で
は、鉄及び銅キレートの存在下、ｐＨによるアスコルビ
ン酸の酸化の動的研究を記載しており、金属イオンがア
スコルビン酸を酸化することを明らかにしている。しか
し、は測定系でのアスコルビン酸の挙動を研究したも
のではない。[0003] First, the Journal of the American Chemical Society (J. Am. Chem.
Soc), 89 , 4176 (1967) and 89 , 7
104 (1967); 90, 3386 (1968) describe a kinetic study of the oxidation of ascorbic acid by pH in the presence of iron and copper chelates, demonstrating that metal ions oxidize ascorbic acid. I have. However, it does not study the behavior of ascorbic acid in the measurement system.
【０００４】特公昭６３−３９８７１号公報では、ア
スコルビン酸塩の悪影響を避ける為に、分析用組成物に
水銀（ＩＩ）サルコシネートを加えている。しかし、有
機ヒドロパーオキシド及び指示薬を含む反応系中へこの
水銀錯体を配合すると、指示薬と金属錯体が反応して偽
陽性を生じてしまう。また、水銀錯体は有害な水銀を含
むので好ましくない。In Japanese Patent Publication No. 63-39871, mercury (II) sarcosinate is added to a composition for analysis in order to avoid the adverse effect of ascorbate. However, when this mercury complex is blended into a reaction system containing an organic hydroperoxide and an indicator, the indicator reacts with the metal complex to generate a false positive. Further, the mercury complex is not preferable because it contains harmful mercury.
【０００５】特公昭６３−６７１３９号公報は、アス
コルビン酸の妨害作用に抵抗する化合物として、コバル
ト（ＩＩＩ）錯体を開示している。しかし、有機ヒドロ
パーオキシド及び指示薬を含む反応系中へこのコバルト
錯体を配合すると、指示薬と金属錯体が反応して偽陽性
を生じてしまう。Japanese Patent Publication No. 63-67139 discloses a cobalt (III) complex as a compound which resists the interfering action of ascorbic acid. However, when this cobalt complex is blended into a reaction system containing an organic hydroperoxide and an indicator, the indicator reacts with the metal complex to generate a false positive.
【０００６】特開平２−２８６０９９号公報は、アス
コルビン酸の妨害を低減する為に、銅（ＩＩ）錯体を生
成する水溶性ポリマーからなる第一酸化体及び無機酸化
体、有機過酸化物または有機Ｎ−ハロ誘導体から選択さ
れる第二の酸化体を包含する系を提案している。しかし
銅（ＩＩ）錯体の酸化速度は遅く、有効な手段ではな
い。Japanese Unexamined Patent Publication (Kokai) No. 2-286099 discloses a primary oxidant and an inorganic oxidant, an organic peroxide or an organic oxidant comprising a water-soluble polymer which forms a copper (II) complex in order to reduce the interference of ascorbic acid. A system comprising a second oxidant selected from N-halo derivatives has been proposed. However, the oxidation rate of the copper (II) complex is slow and is not an effective means.
【０００７】特公平１−４１２２３号公報は、体液成
分測定においてアスコルビン酸を消去する為に、式：Ｒ
１Ｒ２ＮＣＨ２ＣＯＯＨまたはＲ３Ｒ４ＮＸＮＲ５ＣＨ
２ＣＯＯＨで表される化合物の鉄２価もしくは３価の錯
体、またはグルコン酸の鉄２価若しくは３価の錯体を添
加することを提案している。[0007] Japanese Patent Publication No. 41223/1989 discloses a formula: R for eliminating ascorbic acid in the measurement of body fluid components.
1 R 2 NCH 2 COOH or R 3 R 4 NXNR 5 CH
It has been proposed to add an iron divalent or trivalent complex of a compound represented by 2 COOH or an iron divalent or trivalent complex of gluconic acid.
【０００８】特公平４−１８６３０号公報は、過酸化
活性物質検出用組成物に、ポリカルボキシアルキルアミ
ン誘導体の３価の鉄キレートを含ませることを提案して
いる。Japanese Patent Publication No. 18630/1992 proposes that a composition for detecting a peroxide active substance contains a trivalent iron chelate of a polycarboxyalkylamine derivative.
【０００９】特開平６−１４８１６８号公報には、
式：［（ＯＯＣ−Ｘ−ＣＯＯ）３Ｆｅ］Ｍ３（式中、Ｘ
は−（ＣＨ）ｎ−（ここで、ｎは０〜５の整数）で表さ
れるアルキレン基（ａｌｋｙｌｅｎｅ）またはアリル基
（ａｌｌｙｌ）であり、Ｍは一価のカチオンである。）
で表される鉄（ＩＩＩ）錯体が、本出願人により開示さ
れている。JP-A-6-148168 discloses that
Formula: [(OOC-X-COO) 3 Fe] M 3 (where X is
Is an alkylene group or an allyl group represented by-(CH) n- (where n is an integer of 0 to 5), and M is a monovalent cation. )
An iron (III) complex represented by the following formula has been disclosed by the present applicant.
【００１０】またその他の方法として、カナダ特許第
８４４５６４号は、グルコース応答性試薬で含浸した多
孔性部分の他部分に、尿中に存在するアスコルビン酸を
吸着することが出来るイオン交換物質を含む尿試料を受
理する付加部分を有する試験材を提案している。しか
し、イオン交換物質を有するこの試験材は、複雑な構造
をしている上に、分析時間が従来の分析法よりかかると
いう欠点がある。As another method, Canadian Patent No. 844,564 discloses a urine containing an ion exchange substance capable of adsorbing ascorbic acid present in urine in another part of a porous part impregnated with a glucose-responsive reagent. A test material having an additional portion for receiving a sample is proposed. However, this test material having an ion exchange material has a disadvantage that it has a complicated structure and requires a longer analysis time than conventional analysis methods.
【００１１】特公昭５６−３９１９８号公報および米
国特許第４１６８２０５号は、試験紙の処方にアスコル
ビン酸オキシダーゼを配合することにより、アスコルビ
ン酸の影響を排除している。この方法は非常に有効では
あるが、アスコルビン酸の妨害を除去するためには多量
のアスコルビン酸オキシダーゼを必要とするために、不
経済である。また、アスコルビン酸オキシダーゼは、ア
スコルビン酸とは反応するが他の還元性物質とは反応し
ないし、その上非常に不安定な酵素である。JP-B-56-39198 and US Pat. No. 4,168,205 eliminate the effects of ascorbic acid by incorporating ascorbate oxidase into the test paper formulation. While this method is very effective, it is uneconomical because it requires large amounts of ascorbate oxidase to eliminate ascorbic acid interference. In addition, ascorbate oxidase reacts with ascorbic acid but does not react with other reducing substances, and is a very unstable enzyme.
【００１２】また、▲１０▼特公平１−１５２８０号公
報では、還元性妨害物質の影響を避ける為に試料を沃素
酸あるいは沃素酸塩で処理している。しかし、還元性物
質と反応して生成する遊離沃素が、多くの指示薬を酸化
してしまい、偽陽性を示す。また、沃素酸塩も指示薬を
酸化し、バックグラウンドの着色が生じる。In (10) JP-B-1-15280, a sample is treated with iodic acid or iodate in order to avoid the influence of a reducing interfering substance. However, the free iodine produced by reacting with the reducing substance oxidizes many indicators, giving false positives. Also, iodate oxidizes the indicator, resulting in background coloration.
【００１３】本出願人は、▲１１▼特開平６−１４８１
６８号公報中に、一般式：［（ＯＯＣ−Ｘ−ＣＯＯ）３
Ｆｅ］Ｍ３（式中、Ｘは−（ＣＨ）ｎ−（ここで、ｎは
０〜５の整数）で表されるアルキレン基（ａｌｋｙｌｅ
ｎｅ）またはアリル基（ａｌｌｙｌ）であり、Ｍは一価
のカチオンである。）で表される鉄（ＩＩＩ）錯体を開
示している。The applicant of the present invention has proposed (11)
No. 68, a general formula: [(OOC-X-COO) 3
Fe] M 3 (wherein X is-(CH) n- (where n is an integer of 0 to 5).
ne) or an allyl group, and M is a monovalent cation. ) Is disclosed.
【００１４】[0014]
【発明が解決しようとする課題】本発明は、従来技術に
伴うそれぞれの欠点を解決するための、従来にはない構
造の錯体を含有する過酸化活性物質検出用組成物を提供
しようとするものである。SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for detecting a peroxide active substance containing a complex having an unconventional structure in order to solve the respective disadvantages associated with the prior art. It is.
【００１５】[0015]
【課題を解決するための手段】本発明は、有機ヒドロパ
ーオキシド、色原体、および一般式： ［（ＯＯＣ−Ｘ−ＣＯＯ）３Ｆｅ］３− ［式中、Ｘはアリーレン基（ａｒｙｌｅｎｅ）であ
る。］で表される鉄（ＩＩＩ）錯体を含有することを特
徴とする過酸化活性物質検出用組成物を提供する。The present invention relates to an organic hydroperoxide, a chromogen, and a compound represented by the general formula: [(OOC-X-COO) 3 Fe] 3 [where X is an arylene group It is. ] The composition for detecting a peroxide active substance characterized by containing the iron (III) complex represented by the formula:
【００１６】一般に、銅（ＩＩ）及び鉄（ＩＩＩ）イオ
ンは、その酸化能力によってアスコルビン酸をデヒドロ
アスコルビン酸に酸化することが知られている。銅（Ｉ
Ｉ）イオンは、鉄（ＩＩＩ）イオンに比べてその酸化反
応の速度が遅いため、アスコルビン酸による妨害を除去
する能力が鉄（ＩＩＩ）イオンに比べて乏しい。そこ
で、体液成分の測定におけるアスコルビン酸の妨害を克
服するためには、鉄（ＩＩＩ）イオン化合物を使用する
ことが望ましいと考えられる。In general, it is known that copper (II) and iron (III) ions oxidize ascorbic acid to dehydroascorbic acid by their oxidizing ability. Copper (I
I) ions have a lower oxidation reaction rate than iron (III) ions, and therefore have a lower ability to remove interference by ascorbic acid than iron (III) ions. Then, in order to overcome the interference of ascorbic acid in the measurement of the body fluid component, it is considered desirable to use an iron (III) ion compound.
【００１７】鉄（ＩＩＩ）イオン化合物は多種類存在す
るが、一般的な水溶性の鉄（ＩＩＩ）イオン化合物（た
とえば塩化鉄等）を用いた場合、鉄（ＩＩＩ）イオンは
低ｐＨにおいても水溶液中に存在する水分子と速やかに
反応してアコ鉄（ＩＩＩ）錯体を形成する。このアコ鉄
（ＩＩＩ）錯体の酸化還元電位は０．７７Ｖと非常に高
いため、体液成分の測定に用いられる酸化還元系指示薬
と反応してしまい、偽陽性を示す。そのため、上記のよ
うな単なる鉄（ＩＩＩ）イオン化合物は好ましくない。There are many types of iron (III) ion compounds. When a general water-soluble iron (III) ion compound (for example, iron chloride or the like) is used, the iron (III) ion can be dissolved in an aqueous solution even at a low pH. Reacts quickly with water molecules present in it to form aquo-iron (III) complexes. Since the redox potential of this aquo iron (III) complex is as high as 0.77 V, it reacts with the redox indicator used for the measurement of the body fluid component, and shows a false positive. Therefore, a simple iron (III) ion compound as described above is not preferable.
【００１８】ところが、本発明の一般式で表される新規
の鉄（ＩＩＩ）錯体は、体液成分の測定試薬に存在して
も偽陽性結果を生じることなしに、試料中のアスコルビ
ン酸などの還元性物質の妨害を克服することができる。However, the novel iron (III) complex represented by the general formula of the present invention can reduce ascorbic acid or the like in a sample without giving a false positive result even when present in a body fluid component measuring reagent. Overcome the interference of sexual substances.
【００１９】[0019]
【発明の実施の形態】本発明の一般式中のＸはアリーレ
ン基（ａｒｙｌｅｎｅ）、すなわち二価の芳香族炭化水
素である。本発明の一般式で表される新規の鉄（ＩＩ
Ｉ）錯体の好ましい例は、Ｘがフェニレン基のフタル酸
鉄（ＩＩＩ）錯体であり、この化合物を例にとって説明
すると、尿中の潜血を検出する試験紙の場合、試験紙作
成時の含浸溶液中にフタル酸鉄（ＩＩＩ）錯体が１ｍｍ
ｏｌ／ｌ以上、好ましくは１０〜１００ｍｍｏｌ／ｌ含
まれるのが良い。また、その測定系のｐＨは、３〜８、
好ましくは５〜７が良い。BEST MODE FOR CARRYING OUT THE INVENTION X in the general formula of the present invention is an arylene group, that is, a divalent aromatic hydrocarbon. The novel iron (II) represented by the general formula of the present invention
I) A preferred example of the complex is an iron (III) phthalate complex in which X is a phenylene group. Taking this compound as an example, in the case of a test paper for detecting occult blood in urine, an impregnating solution for preparing the test paper Iron (III) phthalate complex in 1mm
ol / l or more, preferably 10 to 100 mmol / l. The pH of the measurement system is 3 to 8,
Preferably, 5 to 7 is good.
【００２０】本出願人は、特開平６−１４８１６８号公
報中に、一般式：［（ＯＯＣ−Ｘ−ＣＯＯ）３Ｆｅ］Ｍ
３（式中、Ｘは−（ＣＨ）ｎ−（ここで、ｎは０〜５の
整数）で表されるアルキレン基（ａｌｋｙｌｅｎｅ）ま
たはアリル基（ａｌｌｙｌ）であり、Ｍは一価のカチオ
ンである。）で表される鉄（ＩＩＩ）錯体を開示した。
しかし本願鉄（ＩＩＩ）錯体は、この特開平６−１４８
１６８号開示の錯体と比較しても、より強力に還元性物
質の影響を除去できる。The present applicant has disclosed in Japanese Patent Application Laid-Open No. 6-148168 a general formula: [(OOC-X-COO) 3 Fe] M
3 (wherein, X is an alkylene group or an allyl group represented by-(CH) n- (where n is an integer of 0 to 5), and M is a monovalent cation. Are disclosed.
However, the iron (III) complex of the present application is disclosed in JP-A-6-148.
As compared with the complex disclosed in Japanese Patent No. 168, the effect of the reducing substance can be more strongly removed.
【００２１】本願発明で使用される鉄（ＩＩＩ）錯体
は、一般式：［（ＯＯＣ−Ｘ−ＣＯＯ）３Ｆｅ］Ｍ
３（式中、Ｍは一価のカチオンである。）で表される様
な電解質状態でもよいし、例えばフタル酸塩と鉄化合物
（例えば塩化鉄）を水溶液中で混合して錯体を形成させ
たものを使用してもよい。The iron (III) complex used in the present invention has a general formula: [(OOC-X-COO) 3 Fe] M
3 (where M is a monovalent cation), or may be a complex formed by mixing a phthalate and an iron compound (eg, iron chloride) in an aqueous solution. May be used.
【００２２】[0022]
【実施例】次に、実施例を示し、本発明を具体的に説明
する。Next, the present invention will be described in detail with reference to examples.
【００２３】尿中潜血の検出用試験片 １．試験片の作製 ワットマン社製濾紙（３ｍｍＣｈｒ；２０×２０ｃｍ）
に後述の組成の溶液１を含浸し、６０℃で２０分間乾燥
させた。さらに溶液２を含浸し、５０℃で１５分間乾燥
させた。得られた試験紙を両面テープを用いてポリエチ
レンテレフタレート（ＰＥＴ）シートに貼り、最終的に
５×５ｍｍの試験紙部分を先端に有する短冊状の試験片
を作成した。また、同様にしてフタル酸鉄（ＩＩＩ）錯
体を含まない試験片を作製した。Test piece for detecting urinary occult blood Preparation of test pieces Whatman filter paper (3 mmChr; 20 × 20 cm)
Was impregnated with a solution 1 having a composition described below, and dried at 60 ° C. for 20 minutes. The solution 2 was further impregnated and dried at 50 ° C. for 15 minutes. The obtained test paper was stuck on a polyethylene terephthalate (PET) sheet using a double-sided tape, and finally a strip-shaped test piece having a 5 × 5 mm test paper portion at the tip was prepared. Similarly, a test piece containing no iron (III) phthalate complex was prepared.
【００２４】フタル酸鉄（ＩＩＩ）錯体は、緩衝液中
で、塩化鉄（ＩＩＩ）六水和物とフタル酸二ナトリウム
とを混合することにより形成される。以下の分量によ
り、２６ｍｍｏｌ／ｌ相当量のフタル酸鉄（ＩＩＩ）錯
体を含有する含浸溶液が調製できる。溶液１ ： 塩化鉄（ＩＩＩ）六水和物 ０．７０ｇ フタル酸二ナトリウム １．６４ｍｇ ３Ｍトリス−マロン酸緩衝液（ｐＨ６．５） ３６．６ｍｌ ラウリル硫酸ナトリウム ３００ｍｇ クメンヒドロパーオキシド ４ｍｌ 精製水 ９．４ｍｌ エタノール ５０ｍｌ 総計 １００ｍｌ溶液２ ３，３，５’，５’−テトラメチルベンチジン ２ｇ ６−メトキシキノリン １ｍｌ ２０％ポリビニルピロリドン・エタノール溶液 ３０ｍｌ トルエン ６９ｍｌ 総計 １００ｍｌThe iron (III) phthalate complex is formed by mixing iron (III) chloride hexahydrate and disodium phthalate in a buffer solution. With the following amounts, an impregnation solution containing 26 mmol / l of iron (III) phthalate complex can be prepared. Solution 1 : Iron (III) chloride hexahydrate 0.70 g Disodium phthalate 1.64 mg 3M Tris-malonic acid buffer (pH 6.5) 36.6 ml Sodium lauryl sulfate 300 mg Cumene hydroperoxide 4 ml Purified water 9. 4 ml ethanol 50 ml total 100 ml solution 2 3,3,5 ', 5'-tetramethylbenzidine 2 g 6-methoxyquinoline 1 ml 20% polyvinylpyrrolidone / ethanol solution 30 ml toluene 69 ml total 100 ml
【００２５】２．試料 プール尿に人血ヘモグロビンおよびアスコルビン酸を表
１に示す濃度で添加、溶解させ、試験尿溶液を調製し
た。2. Samples Human blood hemoglobin and ascorbic acid were added to and dissolved in the pooled urine at the concentrations shown in Table 1 to prepare test urine solutions.
【００２６】３．測定 試験尿溶液中に試験片を漬け、一定時間反応させた後、
高速分光光度計ＣＭＳ−３５ＦＳ（株式会社村上色彩技
術研究所製）を用い、６４０ｎｍの反射率を測定した。3. After immersing the test piece in the measurement test urine solution and reacting for a certain time,
The reflectance at 640 nm was measured using a high-speed spectrophotometer CMS-35FS (manufactured by Murakami Color Research Laboratory).
【００２７】結果を表１にまとめた。反射率値が小さい
ほど着色が濃いことを示し、大きいほど着色が失われて
いることを示す。着色が失われているということは、ア
スコルビン酸の影響を受けていることを示す。The results are summarized in Table 1. The smaller the reflectance value, the deeper the coloring, and the larger the reflectance value, the less the coloring. Loss of color indicates the presence of ascorbic acid.
【００２８】[0028]
【表１】 [Table 1]
【００２９】フタル酸鉄（ＩＩＩ）錯体を含む含まない
に係わらず、アスコルビン酸を含まない状態では両試験
片ともに、人血ヘモグロビン０．０８ｍｇ／ｄｌ含有試
験尿溶液によって良好に青色に発色した。しかし、その
試験尿溶液にアスコルビン酸を２０ｍｇ／ｄｌ添加する
と、フタル酸鉄（ＩＩＩ）錯体の含浸されていない試験
片の場合、青色の発色はほとんど失われた。In a state where ascorbic acid was not contained, both test pieces showed a good blue color by the test urine solution containing human blood hemoglobin 0.08 mg / dl regardless of the presence of iron (III) phthalate complex. However, when ascorbic acid was added to the test urine solution at 20 mg / dl, the blue color was almost lost in the case of the test piece not impregnated with the iron (III) phthalate complex.
【００３０】一方、フタル酸鉄（ＩＩＩ）錯体が含まれ
た試験片ではほとんどアスコルビン酸の影響はなく、さ
らには、アスコルビン酸７５ｍｇ／ｄｌ含有という高濃
度の場合においても良好な青色発色が認められた。On the other hand, the test piece containing the iron (III) phthalate complex had almost no effect of ascorbic acid, and a good blue color was observed even at a high concentration of 75 mg / dl ascorbic acid. Was.
【００３１】[0031]
【発明の効果】以上詳細に説明したように、本願発明を
用いると、試料中の高濃度の還元性物質を良好に排除で
きる。As described in detail above, when the present invention is used, a high concentration of a reducing substance in a sample can be favorably eliminated.
Claims (2)
び一般式： ［（ＯＯＣ−Ｘ−ＣＯＯ）３Ｆｅ］３− ［式中、Ｘはアリーレン基（ａｒｙｌｅｎｅ）であ
る。］で表される鉄（ＩＩＩ）錯体を含有することを特
徴とする、過酸化活性物質検出用組成物。1. An organic hydroperoxide, a chromogen, and a general formula: [(OOC-X-COO) 3 Fe] 3 [wherein X is an arylene group. ] The composition for detecting a peroxide active substance, characterized by containing an iron (III) complex represented by the following formula:
囲第１項に記載の過酸化活性物質検出用組成物。2. The composition for detecting a peroxide active substance according to claim 1, wherein X is a phenylene group.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14203198A JPH11304804A (en) | 1998-04-15 | 1998-04-15 | Peroxide active material deteting composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14203198A JPH11304804A (en) | 1998-04-15 | 1998-04-15 | Peroxide active material deteting composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH11304804A true JPH11304804A (en) | 1999-11-05 |
Family
ID=15305766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14203198A Pending JPH11304804A (en) | 1998-04-15 | 1998-04-15 | Peroxide active material deteting composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH11304804A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020500305A (en) * | 2016-10-28 | 2020-01-09 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | Detection of ascorbic acid in urine samples |
| CN111115671A (en) * | 2018-10-31 | 2020-05-08 | 中国石油化工股份有限公司 | Method for removing iron impurities in aluminum hydroxide |
| CN112945948A (en) * | 2021-02-03 | 2021-06-11 | 迪瑞医疗科技股份有限公司 | Application of nitrogen-oxygen free radical compound as stabilizer in preparation of urine occult blood test paper |
-
1998
- 1998-04-15 JP JP14203198A patent/JPH11304804A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020500305A (en) * | 2016-10-28 | 2020-01-09 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | Detection of ascorbic acid in urine samples |
| US11262350B2 (en) | 2016-10-28 | 2022-03-01 | Siemens Healthcare Diagnostics Inc. | Detection of ascorbic acid in a urine sample |
| CN111115671A (en) * | 2018-10-31 | 2020-05-08 | 中国石油化工股份有限公司 | Method for removing iron impurities in aluminum hydroxide |
| CN112945948A (en) * | 2021-02-03 | 2021-06-11 | 迪瑞医疗科技股份有限公司 | Application of nitrogen-oxygen free radical compound as stabilizer in preparation of urine occult blood test paper |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0123115B1 (en) | Ascorbate interference-resistant composition, device and method for the determination of peroxidatively active substances | |
| FI97551B (en) | Method of analysis, reagent composition and its use for the determination of glucose | |
| Boyer et al. | Reductive release of ferritin iron: a kinetic assay | |
| EP0037056A1 (en) | Process and diagnostic agents for detecting redox reactions | |
| JP3644756B2 (en) | Method for detecting hydrogen peroxide that is not affected by ascorbic acid | |
| CN100350251C (en) | Test strip for creatinine determination | |
| JP3154837B2 (en) | Analytical test method for protein by copper oxidation | |
| JPH11304804A (en) | Peroxide active material deteting composition | |
| EP0141244B1 (en) | Testing agent for detecting a subtance in a body fluid | |
| EP0100217B1 (en) | Process for quantitative determination of substrate treated with oxidase | |
| JPH06148168A (en) | Composite for peroxide active material detection | |
| TSUDZUKI et al. | Studies on Cytochrome α XVIII. The State of Existence of Copper in Cytochrome α and Its Contribution to the Oxidase Activity | |
| JP2955443B2 (en) | Analytical element and analyte detection method | |
| US5106753A (en) | Method for determining manganese level in blood using a porphyrin composition | |
| JP2863491B2 (en) | Reagent composition, test strip and measurement kit | |
| JPH0115280B2 (en) | ||
| US5223438A (en) | Agent composition for detecting redox reaction | |
| HU192806B (en) | Improved test plate apt for the detection of hidden blood and process for the detection of blood | |
| JP2775847B2 (en) | Fructosamine measurement reagent | |
| JPH05209878A (en) | Composition for measuring substance having reroxidizing activity and test piece using the same | |
| JPS6374500A (en) | Specimen for detecting oxalic acid salt in body fluid | |
| JP4071837B2 (en) | Reagent composition for detecting ascorbic acid and test piece | |
| JP3159273B2 (en) | Sorbitol measurement method and composition thereof | |
| JPH04168362A (en) | Determining method for quantity of glutathione | |
| JPH06130056A (en) | Superoxide sensor |